Exicure (XCUR) Shares Outstanding (Diluted Average) (2019 - 2026)
Exicure (XCUR) reported Shares Outstanding (Diluted Average) of $6.4 million for Q1 2026, up 3.09% on a YoY basis from $6.2 million in Q1 2025, and up 1.22% quarter-over-quarter from $6.3 million in Q4 2025.
Exicure (XCUR) Shares Outstanding (Diluted Average) (2019 - 2026) Analysis & Trends
Exicure has reported Shares Outstanding (Diluted Average) for 8 years, with the latest figure at $6.4 million in Q1 2026.
- For the quarter ending Q1 2026, Shares Outstanding (Diluted Average) rose 3.09% year-over-year to $6.4 million; the trailing twelve-month figure through Mar 2026 stood at $6.4 million (up 3.09% YoY), and the FY2025 full-year result was $6.3 million, up 208.19% from the prior year.
- Shares Outstanding (Diluted Average) for Q1 2026 stood at $6.4 million, up from $6.3 million in the prior quarter.
- The five-year high for Shares Outstanding (Diluted Average) was $7.4 million in Q2 2023, with the low at $1.6 million in Q4 2023.
- Historically, Shares Outstanding (Diluted Average) has averaged $4.3 million across 5 years, with a median of $4.6 million in 2022.
- Annual changes were most pronounced in 2022 — Shares Outstanding (Diluted Average) tumbled 95.41% — and 2025, when it surged 261.56%.
- Exicure's Shares Outstanding (Diluted Average) stood at $4.6 million in 2022, then plunged by 65.3% to $1.6 million in 2023, then gained by 27.48% to $2.0 million in 2024, then soared by 208.19% to $6.3 million in 2025, then advanced by 1.22% to $6.4 million in 2026.
- The last three Shares Outstanding (Diluted Average) figures came in at $6.4 million (Q1 2026), $6.3 million (Q4 2025), and $6.3 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Diluted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | 4,489.46 Bn |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | 810.00 |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | 118.76 Bn |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | 1.48 Bn |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 256.30 Mn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | 92.44 Mn |
| 10 | Exicure | 19.38 Mn | 16.77 Mn | - | 6.37 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.37 Mn |
| Dec 31, 2025 | 6.30 Mn |
| Sep 30, 2025 | 6.32 Mn |
| Jun 30, 2025 | 6.26 Mn |
| Mar 31, 2025 | 6.18 Mn |
| Dec 31, 2024 | 2.04 Mn |
| Sep 30, 2024 | 1.90 Mn |
| Jun 30, 2024 | 1.73 Mn |
| Mar 31, 2024 | 1.73 Mn |
| Dec 31, 2023 | 1.60 Mn |
| Sep 30, 2023 | 1.73 Mn |
| Jun 30, 2023 | 7.37 Mn |
| Mar 31, 2023 | 6.29 Mn |
| Dec 31, 2022 | 4.62 Mn |
| Sep 30, 2022 | 4.96 Mn |
| Jun 30, 2022 | 4.50 Mn |
| Mar 31, 2022 | 4.03 Mn |
| Dec 31, 2021 | 2.95 Mn |
| Sep 30, 2021 | 2.93 Mn |
| Jun 30, 2021 | 2.93 Mn |